These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17896920)

  • 1. Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.
    Warlick ED; Smith BD
    Curr Cancer Drug Targets; 2007 Sep; 7(6):541-58. PubMed ID: 17896920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
    Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
    Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
    Nagoshi H; Horiike S; Kuroda J; Taniwaki M
    Curr Mol Med; 2011 Nov; 11(8):678-85. PubMed ID: 21902648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent advances in therapy of myelodysplastic syndromes].
    Hu QJ; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1522-5. PubMed ID: 23257466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
    Feld J; Belasen A; Navada SC
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights.
    Cherian S; Bagg A
    Hematology; 2006 Feb; 11(1):1-13. PubMed ID: 16522543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology of MDS: genomic aberrations].
    Ichikawa M
    Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes: what do hospitalists need to know?
    Zeidan AM; Faltas B; Douglas Smith B; Gore S
    J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
    Tsujioka T; Matsuoka A; Tohyama Y; Tohyama K
    Curr Pharm Des; 2012; 18(22):3204-14. PubMed ID: 22571700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Cancer Invest; 2008 Mar; 26(2):208-16. PubMed ID: 18259954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biology of myelodysplastic syndromes.
    Shih AH; Levine RL
    Semin Oncol; 2011 Oct; 38(5):613-20. PubMed ID: 21943667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving treatment options of myelodysplastic syndromes.
    Verbeek W; Ganser A
    Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.
    Aleshin A; Greenberg PL
    Blood Adv; 2018 Oct; 2(20):2787-2797. PubMed ID: 30352953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
    Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G
    Ann N Y Acad Sci; 2006 Nov; 1089():411-23. PubMed ID: 17261784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.